Passa al contenuto
Merck
Tutte le immagini(3)

Documenti fondamentali

Visualizza tutta la documentazione

P1793

Sigma-Aldrich

Pimozide

≥98% (TLC), powder, D₂ dopamine receptor antagonist

Sinonimo/i:

1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(3)

About This Item

Formula empirica (notazione di Hill):
C28H29F2N3O
Numero CAS:
2062-78-4
Peso molecolare:
461.55
Numero CE:
218-171-7
Numero MDL:
MFCD00055081
Codice UNSPSC:
12352200
ID PubChem:
24277923
NACRES:
NA.77

Nome del prodotto

Pimozide,

Stato

powder

Solubilità

DMSO: 18 mg/mL(lit.)
chloroform: 5 mg/mL
H2O: insoluble(lit.)

Ideatore

Teva

Temperatura di conservazione

2-8°C

Stringa SMILE

Fc1ccc(cc1)C(CCCN2CCC(CC2)N3C(=O)Nc4ccccc34)c5ccc(F)cc5

InChI

1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
YVUQSNJEYSNKRX-UHFFFAOYSA-N

Informazioni sul gene

human ... ABCB1(5243) , CACNA1G(8913) , CYP3A4(1576) , DRD1(1812) , DRD2(1813) , DRD3(1814) , DRD4(1815) , DRD5(1816) , HTR2A(3356) , HTR7(3363) , KCNH1(3756) , KCNH2(3757) , OPRD1(4985)
mouse ... Abcb1a(18671) , Abcb1b(18669)
rat ... Scnn1g(24768)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

D2 dopamine receptor antagonist; binds with high affinity to the cloned 5-HT7 receptor; Ca2+ channel antagonist; antipsychotic

Caratteristiche e vantaggi

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Cyclic Nucleotide-Gated (CNG) and Hyperpolarization Activated Cyclic Nucleotide-Gated (HCN) Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Teva. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302

Classi di pericolo

Acute Tox. 4 Oral

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
SLCL5647
SLCF5333
SLCC3428
SLBX0707
SLBT8468

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Cisapride monohydrate ≥98% (HPLC), solid

Sigma-Aldrich

C4740

Cisapride monohydrate

Droperidol

Sigma-Aldrich

D1414

Droperidol

(+)-cis-Diltiazem hydrochloride ≥99% (HPLC)

Sigma-Aldrich

D2521

(+)-cis-Diltiazem hydrochloride

Domperidone powder, ≥98% (HPLC)

Sigma-Aldrich

D122

Domperidone

S(−)-Verapamil hydrochloride hydrate ≥98% (HPLC), powder

Sigma-Aldrich

V105

S(−)-Verapamil hydrochloride hydrate

Stattic ≥98% (HPLC), powder

Sigma-Aldrich

S7947

Stattic

(±)-Sulpiride

Sigma-Aldrich

S8010

(±)-Sulpiride

Astemizole ≥98% (HPLC)

Sigma-Aldrich

A2861

Astemizole

Junjun Chen et al.
Chemistry & biology, 18(11), 1390-1400 (2011-11-29)
Ubiquitin-specific proteases (USPs) have in recent years emerged as a promising therapeutic target class. We identified selective small-molecule inhibitors against a deubiquitinase complex, the human USP1/UAF1, through quantitative high throughput screening (qHTS) of a collection of bioactive molecules. The top
Holger H H Erb et al.
PloS one, 15(8), e0237248-e0237248 (2020-08-14)
Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs. Several studies have revealed that the signal transducer and activator of transcription (STAT) 5 plays a role in tumour progression and
Tamara Pringsheim et al.
The Cochrane database of systematic reviews, (2)(2), CD006996-CD006996 (2009-04-17)
Neuroleptic drugs with potent D-2 receptor blocking properties have been the traditional treatment for tics caused by Tourette Syndrome. Pimozide is the most studied of these. Use of these medications is declining because of concerns about side effects, and new
Veit Roessner et al.
Neuropharmacology, 68, 143-149 (2012-06-26)
The present review gives an overview of current pharmacological treatment options of tic disorders and Tourette Syndrome (TS). After a short summary on phenomenology, clinical course and comorbid conditions we review indications for pharmacological treatment in detail. Unfortunately, standardized and
Sager J Gosai et al.
PloS one, 5(11), e15460-e15460 (2010-11-26)
The development of preclinical models amenable to live animal bioactive compound screening is an attractive approach to discovering effective pharmacological therapies for disorders caused by misfolded and aggregation-prone proteins. In general, however, live animal drug screening is labor and resource
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.